Fluoroquinolone safety in pediatric patients: a prospective, multicenter, comparative cohort study in France

Clicks: 385
ID: 110586
2003
The rates of PAEs and musculoskeletal PAEs were higher for the FQ group than the control group. This observation supports the American Academy of Pediatrics statement restricting off-label FQ use in pediatric patients to second-line treatment in a limited number of situations.
Reference Key
m2003pediatricsfluoroquinolone Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Chalumeau M;Tonnelier S;D'Athis P;Tréluyer JM;Gendrel D;Bréart G;Pons G; ;;
Journal pediatrics
Year 2003
DOI DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/12777590
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't female male adolescent Child Infant Drug Administration Schedule Comparative Study Prospective Studies preschool risk factors Clinical Trial Multicenter Study anti-bacterial agents / therapeutic use Cohort Studies pmid:12777590 doi:10.1542/peds.111.6.e714 controlled clinical trial martin chalumeau sylvie tonnelier pediatric fluoroquinolone safety study investigators anti-bacterial agents / adverse effects cystic fibrosis / complications cystic fibrosis / pathology fluoroquinolones / adverse effects* fluoroquinolones / therapeutic use france multivariate analysis musculoskeletal diseases / chemically induced respiratory tract infections / complications respiratory tract infections / drug therapy respiratory tract infections / prevention & control sinusitis / complications sinusitis / drug therapy

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.